Actos Linked to Bladder Cancer – Actos Lawsuit Information
December 29th, 2011
Pendley, Baudin & Coffin, L.L.P. is currently evaluating Actos (Pioglitazone Hydrochloride) cases for individuals who have been diagnosed with bladder cancer.
The Type-2 diabetes drug Actos (also marketed as Duetact, Actoplus and Actoplus Met), which was manufactured, developed and distributed by Takeda Pharmaceuticals, has recently been linked to an increased risk of bladder cancer.
In June of 2011, Actos was removed from the markets in France and Germany after studies revealed a potential increased risk of bladder cancer associated with Actos. Shortly thereafter, also in June of 2011, the U.S. Food and Drug Administration (FDA) issued a warning that Actos may be linked to an increased risk of bladder cancer, especially in those who have taken Actos for more than a year. Consequently, the FDA required the maker of Actos to include information about the risk of bladder cancer associated with Actos on its warning label.
The attorneys at Pendley, Baudin & Coffin are here to help you with your Actos lawsuit. Our firm has more than 20 years in pharmaceutical litigation and has represented thousands of consumers who have been injured by pharmaceutical drugs such as Actos. We have helped others triumph over major pharmaceutical companies, and we can help you find justice as well.
If you or a loved one is a diabetic who has been diagnosed with bladder cancer while taking Actos, you have the legal right to seek compensation for your losses and suffering through an Actos lawsuit. For a free consultation to speak with a qualified and experienced lawyer, who will listen to your story, answer your Actos related questions, discuss your options, and offer the help you need to obtain the compensation you deserve, we invite you to phone us at the numbers listed on our website or to fill out the contact us listed below.
This entry was posted in Current Cases, firm-news. Bookmark the permalink.Comments are closed.